Current Report Filing (8-k)
December 04 2018 - 6:03AM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
December 1, 2018
Date of Report
MARKER
THERAPEUTICS, INC.
(Exact name of registrant as specified in
its charter)
Delaware
|
001-37939
|
45-4497941
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
5 West Forsyth Street
Suite 200
Jacksonville, FL
|
|
32202
|
(Address of principal executive offices)
|
|
(Zip Code)
|
(904) 516-5436
Registrant’s telephone number, including
area code
N/A
(Former name or former address, if changed
since last report)
Check the appropriate box below if the Form 8-K is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of
the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company
☐
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act.
☐
As
previously announced by the Company, the Center for Cell and Gene Therapy at Baylor College of Medicine presented data from three
abstracts at the 60
th
American Society of Hematology Annual Meeting between December 1-4, 2018. The Company previously
issued a press release on the presentation of such dates on November 27, 2018 and the press release was filed as an exhibit to
a Form 8-K on the same date. The presentations include: (i) an oral presentation regarding Safety and Efficacy of Multiantigen-Targeted
T Cells for Multiple Myeloma by Premal Lulla, M.B.B.S., Assistant Professor of Medicine at the Center for Cell and Gene Therapy,
Hematology-Oncology, at the Baylor College of Medicine.; (ii) a poster presentation regarding Targeting Lymphomas Using Non-Engineered,
Multi-Antigen Specific T Cells; and (iii) a poster presentation regarding Adoptive T-Cell Therapy for Acute Leukemia Targeting
Multiple Tumor Associated Antigens
The studies describe results achieved using multi-tumor
antigen specific T cells that were developed at the Baylor College of Medicine in the laboratories of Dr. Ann Leen and Dr. Juan
Vera, and exclusively licensed to Marker Therapeutics, Inc.
Copies of the presentation and posters are attached hereto as
Exhibits 99.1, 99.2 and 99.3, respectively. The presentations are available on Marker Therapeutics website at www.markertherapeutics.com
under the caption “Recognition.”
The information furnished pursuant to Item 8.01
on this Form 8-K, including Exhibit 99.1, 99.2 and 99.3 attached hereto, shall not be deemed “filed” for
purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject
to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities
Act or the Exchange Act, except as expressly set forth by specific reference in such a filing.
|
Item 9.01
|
Financial Statements and Exhibits.
|
(d) Exhibits.
*Furnished herewith.
SIGNATURES
In accordance with the requirements of the
Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on this
3
rd
day of December, 2018.
|
MARKER THERAPEUTICS, INC.
(Registrant)
|
|
|
|
BY:
|
/s/ Michael Loiacono
|
|
|
Michael Loiacono
Chief Accounting Officer
|
Marker Therapeutics (NASDAQ:MRKR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Marker Therapeutics (NASDAQ:MRKR)
Historical Stock Chart
From Jul 2023 to Jul 2024